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Background: KSHV is a tumorigenic γ-herpesvirus that has been identified as the etiologic agent of Kaposi’s sarcoma
(KS), a multifocal highly vascularized neoplasm that is the most common malignancy associated with acquired
immunodeficiency syndrome (AIDS). The virus encodes a constitutively active chemokine receptor homologue,
vGPCR that possesses potent angiogenic and tumorigenic properties, and is critical for KSHV pathobiology. To
date, a number of signaling pathways have been identified as key in mediating vGPCR oncogenic potential.
Findings: In this study, we identify a novel pathway, the Wnt/β-catenin pathway, which is dysregulated by vGPCR
expression in endothelial cells. Expression of vGPCR in endothelial cells enhances the nuclear accumulation of β-catenin,
that correlates with an increase in β-catenin transcriptional activity. Activation of β-catenin signaling by vGPCR is
dependent on the PI3K/Akt pathway, as treatment of vGPCR-expressing cells with a pharmacological inhibitor of PI3K,
leads to a decreased activation of a β-catenin-driven reporter, a significant decrease in expression of β-catenin target
genes, and reduced endothelial tube formation.
Conclusions: Given the critical role of Wnt/β-catenin signaling in angiogenesis and tumorigenesis, the findings from this
study suggest a novel mechanism in KSHV-induced malignancies.
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Kaposi’s sarcoma-associated herpesvirus (KSHV) is a
tumorigenic gammaherpesvirus that is the etiologic agent
of Kaposi’s sarcoma (KS). KS is a multifocal, highly vascu-
lar tumor that develops on the lower extremities, mucous
membranes or internal organs. Co-infection with HIV
markedly increases the risk of KS development [1]. Al-
though highly active anti-retroviral therapy (HAART) has
decreased the incidence of AIDS-related KS, it remains an
incurable tumor for which there is no established treat-
ment [2]. KS tumors are characterized by highly proliferat-
ing, elongated, spindle shaped cells of endothelial origin.
The majority of cells in the tumor are latently infected
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unless otherwise stated.lytic proteins [3]. It has been proposed that dysregula-
tion of the viral gene program leads to nonlytic expres-
sion of a virally-encoded G-protein coupled receptor
(vGPCR) homologue [4]. vGPCR has potent angiogenic
and tumorigenic properties and its transgenic expres-
sion in vivo is sufficient to induce the development of
angioproliferative lesions characterized by prominent
inflammation, dysregulated angiogenesis and the pres-
ence of endothelial cells with a spindle morphology [5].
Consequently, vGPCR has become a potential thera-
peutic target for KS.
The exact mechanisms involved in vGPCR-induced
angiogenesis and tumorigenesis are still being eluci-
dated. vGPCR signaling induces the secretion of potent
pro-angiogenic and pro-inflammatory chemokines and
growth factors, such as VEGF, IL-8 and Gro-α that can
promote inflammation, cell transformation, and angio-
genesis through autocrine and paracrine mechanismsral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pathways dysregulated by vGPCR could explain its potent
transforming and oncogenic properties [8,9].
We previously reported that vGPCR activates expres-
sion of COX-2 that drives synthesis of PGE2, a proin-
flammatory molecule linked to tumor angiogenesis and
upregulated in KS lesions [10]. Recent evidence indicates
that PGE2 via signaling through its E2 receptor can acti-
vate β-catenin [11]. β-catenin is a dual function protein
involved in the coordination of cell–cell adhesion and
regulation of gene transcription. Numerous studies have
identified aberrant activation of β-catenin signaling as a
hallmark of many human cancers, which often result
from stabilizing mutation in the genes encoding Wnt/β-ca-
tenin pathway components [12]. However, many cancers
do not contain such mutations [13,14], suggesting that
there are other factors that contribute to β-catenin activa-
tion. Indeed, Wnt/β-catenin signaling is commonly manip-
ulated by oncogenic viruses. Hepatitis C (HCV) virus
activates Wnt/β-catenin signaling, which appears to be key
for the malignant transformation of hepatocytes seen in
hepatocellular carcinoma [15]. Epstein Barr virus (EBV)-
encoded protein, latent membrane protein 2A (LMP2A)
causes β-catenin stabilization through activation of PI3K/
Akt and inactivation of GSK-3β [16].
Here we explore the role of Wnt/β-catenin signaling in
response to vGPCR, a lytic phase viral protein expressed
in KS lesions. We show that expression of vGPCR in
endothelial cells activates Wnt/β-catenin signaling and in-
duces the expression of growth factors and cell-cycle regu-
lators. The results from this study identify a novel
molecular mechanism by which vGPCR modulates host
signaling, which is essential to further understand the
pathobiology of KS and identify novel therapeutic targets.
Results and discussion
Transgenic expression of vGPCR in mice is sufficient to
induce cell proliferation, spindle cell morphology, angio-
genesis and tumorigenesis that leads to formation of le-
sions similar to those in Kaposi’s sarcoma (6). As the
spindle cells in KS lesions are believed to be of endothelial
origin [17], primary human umbilical vein endothelial cells
(HUVECs) were used to confirm the angiogenic properties
of vGPCR. HUVECs transduced with a retrovirus express-
ing vGPCR exhibited spindle-like cell morphology that re-
sembles that of endothelial cells found in KS lesions, while
HUVECs transduced with the vector control (BABE)
retained their cobblestone appearance (Figure 1A). Endo-
thelial cell migration and re-organization into new vessels
are essential steps of neoangiogenesis. vGPCR expres-
sion significantly enhanced migration of HUVECs as
compared to the control cells (Figure 1B). In addition,
vGPCR significantly increased the ability of HUVECs
to form capillary, tube-like networks on a basementmembrane (Figure 1C), which was quantified in (Figure 1D).
Similarly, vGPCR-expressing NIH-3T3 fibroblasts injected
subcutaneously into nude female mice displayed a marked
increase in neovascularization and formation of luminal
structures containing red blood cells (Figure 1E, panels
b & d). The plugs containing the control cells appeared
clear and without newly formed blood vessels or blood
cells (Figure 1E, Panels a & c).
Next, we investigated whether Wnt/β-catenin target
genes and pathway components are altered by vGPCR.
RNA from HUVECs expressing vGPCR or the control
vector was analyzed using a Wnt Signaling Pathway RT2
Profiler PCR Array. Results indicated upregulation of
several β-catenin target genes and ligands, including
cyclin D1, Wnt7A and pygopus 1 (Pygo) at least three-
fold in vGPCR expressing cells compared to control
(Figure 2A and Additional file 1). Cyclin D1 has a role in
cell proliferation as an effector of G1–S progression [18];
Wnt7A is a canonical Wnt ligand that has been impli-
cated to promote vascular growth and angiogenesis [19];
Pygo is a β-catenin binding protein required for the for-
mation of transcriptional complexes [20]. The genes
downregulated at least three-fold by vGPCR include the
negative regulators of Wnt signaling secreted frizzled re-
lated protein 1 (SFRP1) and DKK1, as well as the Wnt
receptors Frizzled 2 and 8. DKK1 and SFRP1 are often
epigenetically inactivated in human cancers, including
colorectal, cervical, prostate, and breast cancer [21,22].
Collectively, these results suggest that expression of
vGPCR may activate Wnt signaling.
β-catenin acts as an intracellular transducer in canon-
ical Wnt signaling. β-catenin is normally localized in the
cytoplasm in an inactive state through its interaction
with a multiprotein complex comprised of axin, aden-
omatous polyposis coli (APC) and two serine/threonine
kinases, glycogen synthase kinase-3β (GSK-3β), and casein
kinase 1 (CK1). Phosphorylation of β-catenin on serine-45
by CK1 followed by phosphorylation on serine-33 and −37
by GSK-3β marks β-catenin for polyubiquitination and
proteasomal degradation. Wnt ligand binding to receptors
on the surface of target cells initiates a cascade of events
leading to disruption of the axin/APC/GSK-3β complex
thus preventing phosphorylation and degradation of β-
catenin. Accumulation of stable, hypophosphorylated β-
catenin in the cytoplasm promotes its translocation to the
nucleus (reviewed in [22]) where it binds T cell-specific
factor(TCF)/lymphoid enhancer-binding factor-1 (LEF-1)
DNA-binding factors to activate transcription of over fifty
target genes involved in cell maintenance, proliferation and
survival, such as cyclin D1, c-myc, VEGFA, MMP-2 and
MMP-9 [22]. Thus, the subcellular distribution of β-
catenin and its transcriptional activation upon vGPCR
expression was next investigated. Levels of β-catenin were
found to be higher in the nucleus of vGPCR-expressing
Figure 1 Angiogenic and transforming properties of vGPCR. (A) HUVECs were infected with the BABE retrovirus expressing vGPCR-GFP or a
BABE-GFP control and imaged at 72 hr post transduction. (B) Cell migration was assayed using BD FluoroBlok cell culture inserts. BABE- and
BABE-vGPCR-expressing HUVECs were loaded into the upper chamber of the inserts and allowed to migrate towards complete media for 12 hr.
Migrated cells were stained with calcein AM and visualized by fluorescence microscopy. Average fluorescence intensity was determined using
ImageJ software. Data are represented as the mean ± SEM (n = 3). **p < 0.001. (C) BABE- and BABE-vGPCR-expressing HUVECs were seeded in a
96-well plate pre-coated with growth factor-reduced Matrigel. Wells were examined for tubule-like structures after 6 hr and tube formation was
quantified by counting the number of branch points (D). Columns represent the average number of branch points from two independent experiments
performed in duplicate ± SE. *p< 0.05. (E) NIH3T3 cells stably transduced with BABE-vGPCR or BABE were mixed with high concentration, growth-factor-
reduced Matrigel. Matrigel-cell suspension was injected subcutaneously into the left and right flanks of 6–8 weeks old athymic NCr-nu/nu mice. n (BABE) = 4;
n (vGPCR) = 6. Plugs were retrieved, fixed and processed for hematoxylin-eosin staining. Macroscopic appearance of representative plugs containing
BABE- (panel a) or BABE-vGPCR-expressing cells (panel b). Microscopic examination of hematoxylin-eosin stained sections from Matrigel plugs containing
BABE- (panel c) or BABE-vGPCR-expressing cells (panel d). vGPCR plugs show an increase in formation of blood vessels containing red blood cells.
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blot analysis of nuclear and cytoplasmic fractions
(Figure 2B). These observations were confirmed by im-
munofluorescence analysis, demonstrating that more β-
catenin accumulates in the nucleus of vGPCR-expressing
cells (Figure 2C).
To confirm that vGPCR leads to accumulation of tran-
scriptionally active β-catenin, HUVEC expressing vGPCR
were transfected with a β-catenin/LEF1-dependent Top-
Flash reporter construct harboring three LEF/TCF binding
sites upstream of the thymidine kinase minimal promoter,
and 24 hr later, the luciferase activity of the reporter was
measured. The TopFlash-specific promoter activity was
significantly increased by vGPCR (Figure 2D). Consistentwith these results, quantitative RT-PCR analysis indi-
cated a significant increase in expression of β-catenin
target genes cyclin D1, MMP-9 and VEGFA by vGPCR
(Figure 2E). VEGFA, cyclin D1 and MMP-9 have been
implicated in angiogenesis and KS development [23,24,25].
To substantiate the role of β-catenin in vGPCR-mediated
angiogenesis, we utilized siRNA to decrease expression of
β-catenin in cells stably expressing vGPCR (Figure 3A).
Silencing β-catenin led to a decrease in endothelial tube
formation, confirming a positive role of β-catenin in
vGPCR-mediated angiogenesis (Figure 3B and C). How-
ever, β-catenin knockdown in vGPCR-expressing endo-
thelial only slightly decreased the expression of the
angiogenic factor cyclin D1 (data not shown). This may
Figure 2 vGPCR activates Wnt/β-catenin signaling in endothelial cells. (A) Total RNA was isolated from BABE- and BABE-vGPCR-expressing HUVECs
and analyzed with Human Wnt signaling pathway RT2 Profiler PCR array (SABiosciences, Frederick, MD). Genes that displayed greater than 3-fold change
over control were considered significant. (B) HUVECs expressing vGPCR or BABE vector were serum starved for 16 hr and fractionated into cytosolic and
nuclear components. Protein fractions were analyzed by Western blot with an anti-β-catenin antibody. Anti-γ-tubulin, and anti-H3 Western
blots were included as controls for the purity of the fractionation procedure. β-actin served as a loading control. The densitometry data presented
below the bands are arbitrary units normalized to the respective loading control (α-tubulin or histone H3). (C) HUVECs stably transduced with BABE or
BABE-vGPCR were seeded on glass coverslips and stained with rabbit polyclonal antibody to β-catenin followed by AlexaFluor 555-conjugated
anti-rabbit IgG. Nuclei were counterstained with DAPI. 40 X magnification. (D) HUVECs expressing vGPCR or control vector (BABE) were transiently
transfected with TOPflash or FOPflash firefly luciferase-expressing plasmids. pRL-TK plasmid expressing Renilla luciferase was co-transfected as a control.
Forty-eight hr after transfection, the cells were collected in lysis buffer and luciferase expression in cell lysates was measured and normalized to Renilla
activity. Data are presented as the mean of results from two independent experiments each performed with triplicate transfections. ***p < 0.001. (E)
Cyclin D1, MMP-9 and VEGFA mRNA levels in BABE-vGPCR- and BABE-expressing HUVECs were analyzed by qRT-PCR in triplicate. Each sample
was normalized to the level of 36B4 expression. The data are presented as fold change (mean +/− SEM) relative to BABE control sample.
*p < 0.05; ***p < 0.001.
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Figure 3 Effect of β-catenin knockdown on tubule formation and β-catenin target gene expression. HUVECs expressing vGPCR were transiently
transfected with siRNA to β-catenin or with non-silencing siRNA control. (A) 72 hr following β-catenin silencing, knockdown efficiency was determined
by qRT-PCR. β-catenin mRNA levels were normalized to 36B4 expression. (B) vGPCR-HUVECs were plated on Matrigel as described in Materials and
Methods and allowed to form tubules. (C) The number of branch points was determined 6 hr after plating. The data is presented as an average of two
independent experiments performed in duplicate. ***p< 0.001.
Angelova et al. Virology Journal  (2014) 11:218 Page 5 of 10be due to residual β − catenin signaling activity in the
knockdown cells, or the contribution of other signaling
pathways that may also regulate expression of this gene.
These results suggest that the increased angiogenic po-
tential of vGPCR is mediated, at least in part, through
activation of Wnt/β-catenin signaling. Further work is
needed to determine if β-catenin knockdown will dis-
rupt angiogenesis in vivo.
Activation of Wnt/β-catenin signaling by GPCRs has
been previously demonstrated. There is evidence that the
receptors for Wnt ligands, the Frizzled receptors, are het-
erotrimeric GPCRs [26,27]. In addition, classical GPCR
proteins like the PGE2 receptor on colon cancer cells and
the α-andrenergic receptors on cardiomyocytes, have been
shown to activate canonical β-catenin signaling in a Wnt-
independent manner (see review [28]). We next explored
the contribution of COX-2 to Wnt/β-catenin activation by
vGPCR. vGPCR-expressing HUVECs were transfected
with the β-catenin reporter TOPflash, treated with the se-
lective COX-2 inhibitor NS-398, and analyzed for lucifer-
ase expression. Inhibition of COX-2 with NS-398 failed to
inhibit vGPCR-mediated activation of TOPflash, as there
was no detected difference in activation of the reporter be-
tween treated and untreated cells (Figure 4A). Likewise,
inhibition of COX-2 by NS-398 was also not sufficient to
inhibit vGPCR-induced tube formation (Figure 4B and C),
and the elevated expression of β-catenin target genes,
cyclin D1, MMP-9 and VEGFA, was unaffected by COX-2
inhibition (Figure 3D). Collectively, these results suggest
that activation of Wnt/β-catenin by vGPCR occurs
through a COX-2-independent mechanism.
Activation of the PI3K/Akt signaling axis appears to
be fundamental in vGPCR oncogenesis [29,30]. A reportby Martin et al. [29] demonstrates that an isoform of
PI3K, PI3Kγ, is necessary for vGPCR sarcomagenesis, as
its inhibition causes tumor regression. Upon activation,
PI3K activates its downstream effector Akt/protein kin-
ase B (Akt) by promoting its phosphorylation at residues
Ser 473 and Thr 308. Activated Akt promotes endothe-
lial cell migration and differentiation through phosphor-
ylating a wide range of downstream substrates. One
downstream target of Akt is GSK-3β, which undergoes
auto-inhibition when phosphorylated. In the absence of
phosphorylation by GSK-3β, β-catenin cannot be tar-
geted for degradation and is thus stabilized promoting
its accumulation and subsequent nuclear translocation.
Another study showed that activated PI3K/Akt can
phosphorylate adherence junctions-associated β-catenin
on S552, which causes β–catenin to dissociate from the
junctions and translocate to the nucleus [31]. Skurk
et al. reported that β-catenin–enhanced endothelial
cell differentiation and migration are inhibited by
PI3K/Akt inhibition, suggesting that Wnt/β-catenin
promotes angiogenesis and blood vessel growth via the
induction of PI3-K/Akt signaling in endothelial cells [32].
Therefore, the effect of PI3K inhibition on vGPCR-driven
activation of β-catenin signaling was investigated next.
TOPflash activity in vGPCR-expressing cells was signifi-
cantly decreased following PI3K inhibition with LY294002
(Figure 5A). This was not due to increased cytotoxicity, as
the compound resulted in a minimal reduction in cell
viability (Figure 5D). In addition, inhibition of PI3K
reduced the formation of capillary endothelial tubes
(Figure 5B and C) and the expression of β-catenin tar-
get genes (Figure 5E), suggesting involvement of PI3K
in vGPCR-induced activation of the β-catenin pathway.
Figure 4 Effect of COX-2 inhibition on Wnt/β-catenin activation by vGPCR. (A) HUVECs expressing vGPCR were transiently transfected with
TOPflash and pRL-TK plasmids. Twenty-four hr after transfection, the cells were treated with 100 μM of NS-398 or vehicle control for 24 hr. Cell lysates
were collected and analyzed for luciferase expression. Data are presented as the mean from two independent experiments each performed in
duplicate. ns – not significant. (B) HUVECS expressing vGPCR were pretreated with 100 μM NS-398 or vehicle control for 24 hr and seeded
onto Matrigel-coated wells in medium supplemented with 100 μM NS398 or vehicle control for 6 hr. (C) The number of branch points was determined
and expressed as the average from three replicate wells. ns – not significant. (D) Cyclin D1, VEGFA and MMP-9 mRNA expression was measured by
qRT-PCR in control (BABE), vGPCR- expressing cells, and vGPCR-expressing cells that were treated with 100 μM NS-398 for 24 hr. The data are presented
as fold change (mean +/− SEM) relative to control (BABE) sample. *p < 0.05; **p < 0.01; ns – not significant.
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PI3K/Akt occurs through AKT-mediated phosphorylation
of GSK-3β or through direct phosphorylation of β-catenin
by AKT. Further understanding of the cross talk between
Wnt/β-catenin signaling and PI3K/Akt pathways and the
role they play in vGPCR pathogenesis will help further
elucidate the key steps in the angiogenic process and may
help establish Wnt/β-catenin and PI3K pathways as novel
therapeutic targets for treatment of KS.Methods
Cell lines and retrovirus infection
Primary human umbilical vein endothelial cells (HUVECs)
(Lonza, Allendale, NJ) were grown in M-199 media sup-
plemented with 20% fetal bovine serum (FBS), 1% Penicil-
lin/Streptomycin and 50 μg/mL ECGS (BD Biosciences,
San Jose, CA) on vessels coated with 2% gelatin. Recom-
binant retroviral vectors expressing either GFP alone
(BABE) or GFP and KSHV ORF74 (BABE-vGPCR) [10]
Figure 5 Effect of PI3K inhibition on Wnt/β-catenin activation by vGPCR. (A) HUVECs expressing vGPCR were transiently transfected with
TOPflash and pRL-TK plasmids. Twenty four hr after transfection, the cells were treated with 25 μM LY294002 or vehicle control for an additional
24 hr. Cell lysates were collected and analyzed for luciferase expression as described in Figure 3A. (B) HUVECs expressing vGPCR were pretreated
with 25 μM LY294002 or vehicle control for 12 hr and plated in 96-well plate coated with Matrigel in the presence of LY294002. (C) The number
of branch points was determined as in Figure 3B. ***p < 0.001. (D) Cytotoxicity of increasing doses of LY294002 was determined by MTT assay
*p < 0.05. (E) Cyclin D1, VEGFA and MMP-9 mRNA expression was measured by qRT-PCR in control (BABE), vGPCR- expressing cells, and vGPCR-
expressing cells that were treated with 50 μM LY294002 for 24 hr. The data are presented as fold change (mean +/− SEM) relative to control
(BABE) sample. *p < 0.05; **p < 0.01.
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complete media supplemented with 8 μg/mL polybrene
(hexamethidrine bromide) (Sigma). GFP fluorescence was
used to determine transduction efficiency between 48–
72 hr post-infection. For all experiments, transduction ef-
ficiency was >80%.
Quantitative real-time RT-PCR (qRT-PCR)
Total RNA was harvested from cells using the Qiagen
RNeasy Kit (Qiagen) according to the manufacturer’sinstructions. Total RNA (500 ng) was reverse transcribed
using iScript cDNA Synthesis kit (Bio-Rad) and used in a
qPCR using SYBR Green supermix (Bio-Rad). Oligo-
nucleotide primers (Integrated DNA Technologies) used
are as follows: cyclin D1 forward (5′-CGCCCTCGGTG
TCCTACTTC-3′), cyclin D1 reverse (5′-GACCTCCTCC-
TCGCACTTCTG-3′); VEGFA forward (5′- GGCAGAA
GGAGGAGGGACAGAATC -3′), VEGFA reverse (5′- CA
TTTACACGTCTGCGGATCTTGT -3′); MMP-9 forward
(5′-AGACGGGTATCCCTTCGACG-3′), MMP-9 reverse
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ward (5′-TTCCAACGCTATCAACCTGC-3′), DKK1 re-
verse (5′- CAAGGTGGTTCTTCTGGAATACC-3′);
c-myc forward (5′- GCCACGTCTCCA-CACATCAG-
3), c-myc reverse (5′-TCTTGGCAGGAGGATAGTC
CTT-3′); 36B4 forward (5′-TGGAGACGGATTACACC
TTC-3′), 36B4 reverse (5′-CTTCCTTGGCTT-CAACC
TTAG-3′); Relative quantitation was determined using
the comparative CT method with data normalized to
36B4 and calibrated to the average ΔCT of BABE con-
trol at the specific time points.
Western blotting
Cells were lysed in RIPA buffer (25 mM TrisHCl pH 7.6,
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate,
0.1% SDS) supplemented with protease inhibitors. Pro-
tein samples were separated by SDS-PAGE and trans-
ferred to a nitrocellulose membrane. Membranes were
blocked in 5% non-fat dry milk and incubated in primary
antibody overnight at 4°C, followed by horseradish
peroxidase-conjugated anti-mouse or anti-rabbit second-
ary antibodies (Invitrogen). Antibody-protein complexes
were detected with ECL Plus (Amersham Biosciences)
and exposed to chemiluminescent film. Primary anti-
bodies: mouse anti-β-catenin (Santa Cruz Biotechnology;
1:500 dilution), mouse anti-β-actin (Abcam; 1:5,000),
mouse anti-γ-tubulin (Abcam; 1:1000), anti-Histone 3
(Cell Signaling; 1:1000). Densitometric analysis was per-
formed using ImageJ software (National Institutes of
Health, Bethesda, MD).
Luciferase analyses
HUVECs were transiently transfected with the TCF/LEF-1
reporter plasmid TOPflash, which contains multimeric
TCF/LEF-1 sequences upstream of a firefly luciferase re-
porter gene. FOPflash plasmid containing mutated TCF/
LEF-1 binding sites was used as a specificity control for
TOPflash. Plasmids were purchased from Millipore
(Bedford, MA). A Renilla luciferase-expressing plasmid
pRL-TK (Promega) was co-transfected as an internal
control. Cells were transfected with 1 μg of either TOP-
flash or FOPflash DNA and 0.1 μg of Renilla plasmid
using the Neon transfection system (Invitrogen) ac-
cording to the manufacturer’s instructions. Twenty-four
hr after transfection, luciferase activity was assayed with
a dual-luciferase reporter assay kit (Promega) and mea-
sured in a luminometer (Berthold Technologies). For
each sample, the firefly luminescence signal was nor-
malized to the corresponding Renilla signal.
Small interfering RNA (siRNA) transfection
Cells were transfected with 100 nM siRNA to β-catenin
(Santa Cruz) or the same concentration of non-silencing
siRNA (Santa Cruz) using the NEON transfectionsystem (Invitrogen). Twenty-four hours later cells were
serum starved for 24 hr and harvested for subsequent
assays.
Isolation of cytoplasmic and nuclear fractions
Cytoplasmic and nuclear fractions were isolated from
cells using a nuclear extract kit (Active Motif, Carlsad,
CA) according to the manufacturer’s protocol. Resulting
fractions were separated on SDS-PAGE and immuno-
blotted for β-catenin, H3, and γ-tubulin as described
above.
Immunofluorescence
Cells were seeded onto glass coverslips coated with 0.2%
gelatin, and infected with BABE or BABE-vGPCR as de-
scribed above. At indicated time points after infection,
cells were fixed in 2% paraformaldehyde (Ted Pella) and
permeablized in 0.1% Triton X-100. The cells were
blocked in 5% BSA for 1 hr at room temperature and in-
cubated with primary antibodies for 1 hr at room
temperature followed by incubation with AlexaFluor-
conjugated secondary antibodies and DAPI. Coverslips
were mounted with ProLong gold antifade (Invitrogen)
and imaged at 40X using a Zeiss Axioplan II microscope
(Carl Zeiss).
Migration assays
Cells were loaded into 8 μm FluoroBlok 24-well multi-
well insert system (BD Biosciences) at 2x104 cells per in-
sert, in 200 μl of M-199 supplemented with 0.5% FBS.
The bottom chamber of the insert was loaded with
800 μl of complete M-199. The cells were incubated at
37°C in 5% CO2 and allowed to migrate for 12 hr. The
inserts were then labeled with calcein AM (Molecular
Probes) and visualized by fluorescent microscopy. Three
random fields from each insert were captured with a
Nikon TE200 inverted fluorescent microscope (Nikon
Instruments) and the average fluorescence intensity was
determined by ImageJ software.
Endothelial tube formation assay
Cells were trypsinized and resuspended in 100 μl of low
serum (0.5%) M-199 medium without ECGS. Cells were
seeded in a 96-well plate coated with 100 μl/well of
growth factor reduced Matrigel (BD Bioscience) at a
density of 1x104 cells/well and incubated at 37°C for
6 hr. Tube formation was observed using a phase-
contrast microscope. The number of tubes was quanti-
fied by counting the number of tube branch points.
In vivo Matrigel plug angiogenesis assay
Animal experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) at Tulane
University. NIH3T3 cells were stably transduced with
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lation, 2 × 106 cells were harvested in 200 μl of
phenol-free, serum-free media containing 10 units/ml
of heparin, and mixed with 200 μl of high concentra-
tion, growth-factor-reduced Matrigel (BD Bioscience).
400 μl of the Matrigel-cell suspension was injected
subcutaneously into the left and right flanks (2 sites
per mouse) of anaesthetized, 6–8 weeks old nu/nu
athymic mice. Plugs were retrieved 7 days after im-
plantation and fixed in 10% formalin overnight. After
fixation, plugs were rinsed in PBS, paraffin embedded
sectioned and stained with hematoxylin-eosin.
Statistical analysis
Significant differences between experimental groups were
determined by Student’s t-test or one-way analysis of
variance (ANOVA) followed by Tukey’s post hoc t test
using GraphPad Prism 4 software. Data are presented as
the means ± standard error of the means (SEM).
Reagents
The PI3K inhibitor LY294002 was obtained from Cell
Signaling; the selective COX-2 inhibitor NS-398 was
purchased from Cayman Chemicals. The concentration
for each inhibitor is specified in the figure legends.
Additional file
Additional file 1: Wnt Signaling Pathway RT2 Profiler PCR Array
results for KSHV infected HUVEC.
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